The effect of cannabidiol on canine neoplastic cell proliferation and mitogen-activated protein kina

Dated: November 28, 2020


  1. The objectives of this study was to explore the anti-proliferative and cell death response associated with in vitro treatment of canine cancer cell lines with CBD alone and combination with common chemotherapeutics, as well as investigation into major proliferative pathways (eg, p38, JNK, AKT and mTOR) potentially involved in the response to treatment with CBD.

  2. Five established canine neoplastic cell lines were obtained and used for all experiments; a cell line of epithelial mammary gland carcinoma cell line—CMT12 (provided by Dr Curtis Byrd), a B cell lymphoma lineage—17-71 (provided by Dr Angela Wheeler), and three mesenchymal osteosarcoma lines HMPOS (provided by Dr Rodney Page), D17 (#CCL-183; ATCC, Manassas, Virginia) and Abrams (provided by Dr Angela Wheeler). All cell lines were deemed mycoplasma free by polymerase chain reaction from the Animal Health and Diagnostic Laboratory at Cornell University.

  3. All statistical analysis regarding percent proliferating cells as measured by MTT assay and Annexin-FITC assay were performed using JMP Pro (v. 11.2.1; SAS Institute Inc., Cary, North Carolina).

  4. CBD is effective at hindering cell proliferation and induction of autophagy and apoptosis rapidly across neoplastic cell lines and further clinical trials are needed to understand its efficacy and interactions with traditional chemotherapy. This study demonstrated the in vitro anti-neoplastic properties of CBD on five canine cancer cell lines representative of all three major cancer lineages when used as a single agent, as well as in combination with commonly utilized chemotherapeutics. Our results are in accordance with other cannabinoid based research and offers initial insights into this field of research in veterinary medicine. Pending additional research, CBD and other cannabinoids may be utilized as adjuvant therapy for canine cancer patients, but must take into account the current chemotherapeutic protocol with trepidation because of potential drug-drug interactions.


For further information: https://pubmed.ncbi.nlm.nih.gov/33247539/


0 views0 comments